En Es
Categories

Industry News

Companies with Lab-Developed Tests Raise USD 2 Billion

By Labmedica International staff writers
11 Oct 2017

Image: Companies with laboratory-developed tests are attracting increasing investor interest and raised over USD 2 billion between January and August 2017 (Photo courtesy of iStock).Companies with laboratory-developed tests (LTDs), tests performed by laboratories owned by IVD companies and others, are attracting increasing investor interest and raised over USD 2 billion between January and August 2017. These are the latest findings of Kalorama Information, (New York, NY, USA), an independent medical market research firm.

LDTs, also called as "home-brew tests" or "in-house tests" were historically low-volume, simple and well-characterized tests for low-risk diagnostic applications. However, in recent years, there has been increased focus and attention on the emergence and growing use of complex LDTs based on technologies such as polymerase chain reaction (PCR), microarrays, next generation sequencing, or other complex technology. High-risk, complex tests have now been developed as LDTs in order to provide clinical results to physicians and their patients.

Presently, LDTs are being used for complex testing which smaller laboratories are not equipped or do not choose to handle and are used for a variety of medical conditions. There are all types of LDTs, including histology and molecular testing to immunoassays; or equipment-intensive testing such as mass spectrometry or flow cytometry. The largest segments of the LDTs market are oncology, genetic (inherited) disorders, and infectious disease, although these tests can be developed and used for virtually all types of disorders.

The significant activity in the development of new LDTs, increasing revenues from current LDTs, and the large addressable markets for several emerging LDTs has attracted the interest of investors as well as of other companies looking for acquisitions. For instance, in 2016, the companies included in Kalorama’s report raised over USD 750 million, although this amount was much smaller in comparison to the over USD 2 billion raised between January and August 2017.

The LDTs market has also witnessed a significant number of acquisitions in recent years, with the major companies making several acquisitions to achieve their current market positions, while smaller clinical laboratories have also been making acquisitions. A number of new companies also continue to be founded, thus providing a continuous stream of smaller companies trying to achieve growth, which may come through acquisitions or they may end up being acquired. Hence, consolidation among companies and laboratories offering LDTs is expected to continue in the future.

Related Links:
Kalorama Information



E-mail Print
FaceBook Twitter Google+ Linked in

Additional news

20 Jun 2018
Infectious Disease Testing to Remain Driver for Diagnostic Market
The global market for infectious disease products is expected to record a 60% higher growth than the overall world market for in vitro diagnostics, with tests for infectious diseases representing more than one-fourth of the entire testing market. These are the latest findings of Kalorama Information, an independent medical market research firm.
Read More
20 Jun 2018
Advantech Launches Healthcare Infotainment Terminals
Advantech Co., Ltd, a provider of medical computing systems and services, has launched the HIT-W183 and HIT-W153 healthcare infotainment terminals, which are specifically designed for a wide range of hospital applications.
Read More
12 Jun 2018
AI Software Platform Aims to Synthesize Biomedical Knowledge
nference, which focuses on artificial intelligence (AI)-powered life sciences, is developing an AI software platform to synthesize the exponentially growing biomedical knowledge.
Read More
11 Jun 2018
MEDICA 2018 Launches App Competition for Smart Products
The search for the best health app solutions in the world has begun with the launch of the seventh MEDICA App Competition. The competition is meant for applications for smart phones, smart watches, tablets or AR/VR glasses, but excludes fitness or wellness applications. All submitted applications for the MEDICA App Competition 2018 must have a connection with professional medical technology, and applications from start-ups that are still in the early stage are also invited.
Read More
07 Jun 2018
New AI Algorithm Makes Liver Cancer Surgery Safer
Researchers at the Fraunhofer Institute for Medical Image Computing MEVIS have developed algorithms that analyze patients’ imaging data and calculate surgical risks, making liver cancer surgery safer and easier to plan. Researchers at Fraunhofer have been working on image-processing algorithms for use in medicine since 1998. The method is now widely known among physicians as MEVIS analysis and has become established in practice.
Read More
07 Jun 2018
AI-based Interpretation Tool Receives CE Certification
qXR, an AI-based chest X-ray interpretation tool that detects 15 of the most common chest X-ray abnormalities with an accuracy of more than 90%, has received CE certification. Developed by healthcare AI start-up Qure.ai, qXR has been trained on more than one million chest X-rays and uses a heat map or bounding box to point out abnormalities to the clinician, aiding rapid con?rmation in just milliseconds.
Read More
07 Jun 2018
Global Radiation Detection Market to Reach USD 2 Billion by 2022
The global radiation detection, monitoring, and safety market is expected to grow at a CAGR of 5.7% from USD 1.71 billion in 2017 to USD 2.26 billion by 2022. The market is likely to be driven by rising security threats, increasing prevalence of cancer across the world, growing safety awareness among people working in radiation-prone environments, rising safety concerns following the Fukushima disaster, expanding security budgets of global sporting events, increase in the number of PET/CT scans, growing usage of nuclear medicine and radiation therapy for diagnosis and treatment, and use of drones for radiation monitoring. However, nuclear energy alternatives such as renewable energy, nuclear power phase-out, and shortage of nuclear power workforce, are likely to limit the market growth.
Read More
06 Jun 2018
Siemens Healthineers and ScreenPoint Medical to Develop AI-Based Apps
Siemens Healthineers and ScreenPoint Medical have entered into a partnership to develop artificial intelligence (AI)-based applications for breast imaging. As part of the arrangement, Siemens Healthineers will also acquire a strategic minority stake in ScreenPoint Medical.
Read More
06 Jun 2018
Qure.ai Partners with Teleradiology Solutions for Smarter Diagnoses
Healthcare artificial intelligence (AI) provider, Qure.ai has partnered with Teleradiology Solutions and Telerad Tech to enable smarter and faster diagnoses of X-ray and CT scan data, and reduce costs.
Read More
Copyright © 2000-2018 TradeMed.com. All rights reserved. | Terms And Conditions